Most are going that route, including them. When the S-1 was filed (the IPO has now been abandoned), said they would be using CRISPR (electroporation wasn't going to be used) to knockout genes that encode inhibitory receptors, and could knockout/in genes to improve persistence, with them hinting at B2M/CIITA KO and HLA-E KI. But no additional details, such as editing efficacy were presented.
News 
Market Data 
Discover 
